Skip to main content
. 2008 Feb 21;118(3):1085–1098. doi: 10.1172/JCI32830

Figure 3. GH treatment is associated with increased thymic density and TREC frequency in HIV-1–infected adults.

Figure 3

(A) Comparison of changes in the GH arm versus the control arm over the first year of the study demonstrated significant increases in thymic density in GH recipients at 6 and 12 months after GH initiation. A modest, nonsignificant decrease in thymic density was observed between month 6 and month 12, commensurate with GH dose reduction and consistent with a dose-response effect of GH on the thymus. No notable changes in thymic density were seen in the absence of GH. (B) The frequency of PBMC TRECs was also increased with GH treatment during the first year of the study. (C) Comprehensive regression analysis, including crossover data of GH treatment of observational controls, demonstrates that GH treatment (circles) is associated with significant increases in thymic density and PBMC TREC frequency compared with no GH. Estimated changes with 95% CIs are displayed. Regression analysis estimated the effects of 6 months (thymic density) or 1 year (PBMC TRECs) of GH treatment compared with changes in the absence of GH. Median values are displayed in A and B. CIs and additional data are shown in Tables 2 and 3. *P < 0.05 for comparison of GH versus no GH.